Author details

Full Name

William M Carroll

Affiliation

ORCID

Career Start Year

1977

Papers

124

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36149605	Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.		2023
35084124	Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.	Brain and Behavior	2022
36157631	Global Advocacy in Action: World Brain Day 2021 Dedicated to Stopping Multiple Sclerosis.	Neurology: Clinical Practice	2022
35216788	Response to treatment in NMOSD: the Australasian experience.	Multiple Sclerosis and Related Disorders	2022
34387513	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.	Multiple Sclerosis Journal	2022
34566866	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis.	Front Neurol	2021
32612571	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation.	Front Neurol	2020
32006158	The clinical profile of NMOSD in Australia and New Zealand.	J Neurol	2020
31813850	The global burden of neurological disorders: translating evidence into policy.	Lancet Neurol	2020
33039944	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.	Multiple Sclerosis and Related Disorders	2020
32702326	World Brain Day 2020: move together to end Parkinson's disease.	Lancet Neurology, The	2020
32675076	Serum neurofilament light as a biomarker in progressive multiple sclerosis.	Neurology	2020
30879892	The global burden of neurological disorders.	Lancet Neurology, The	2019
30594104	Clean air for Brain Heath; ongoing agenda of 2018 World Brain Day.	Journal of the Neurological Sciences	2019
31138860	Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome.	Scientific Reports	2019
29780610	A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS study.	Multiple Sclerosis Journal - Experimental, Translational and Clinical	2018
30057580	Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome.	Frontiers in Immunology	2018
30248527	Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.	Journal of Neuroimmunology	2018
30289380	2018 Editors' commentary.	Multiple Sclerosis Journal	2018
30128151	Tryptophan and arginine catabolic enzymes and regulatory cytokines in clinically isolated syndrome and multiple sclerosis.	Clinical and Translational Immunology	2018
29627005	Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.	Journal of the Neurological Sciences	2018
29451442	2017 McDonald MS diagnostic criteria: Evidence-based revisions.	Multiple Sclerosis Journal	2018
29451441	MSJ 2018-editorial comment.	Multiple Sclerosis Journal	2018
29275977	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.	Lancet Neurol	2018
28167940	Narrowband UVB Phototherapy for Clinically Isolated Syndrome: A Trial to Deliver the Benefits of Vitamin D and Other UVB-Induced Molecules.	Frontiers in Immunology	2017
28690849	Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis.	Clinical and Translational Immunology	2017
28550069	Incidence and prevalence of NMOSD in Australia and New Zealand.	J Neurol Neurosurg Psychiatry	2017
28716272	The need for a Global Neurology Alliance.	Journal of the Neurological Sciences	2017
28617321	Evolving Identification of Blood Cells Associated with Clinically Isolated Syndrome: Importance of Time since Clinical Presentation and Diagnostic MRI.	International Journal of Molecular Sciences	2017
28607754	Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS.	Multiple Sclerosis Journal - Experimental, Translational and Clinical	2017
27689339	Circulating immune cells in multiple sclerosis.	Clinical and Experimental Immunology	2017
27751564	Revising the ICD: stroke is a brain disease.	Lancet, The	2016
26849221	Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.	PLoS ONE	2016
27452915	World Brain Day 2016: celebrating brain health in an ageing population.	Lancet Neurology, The	2016
26541323	Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.	Journal of Clinical Neuroscience	2016
25175564	Oligodendrocyte Lineage Cells in Chronic Demyelination of Multiple Sclerosis Optic Nerve.	Brain Pathology	2015
25663410	Body weight-based natalizumab treatment in adult patients with multiple sclerosis.	Journal of Neurology	2015
25602009	Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females.	Journal of Neurology, Neurosurgery and Psychiatry	2015
26092914	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.	Neurology	2015
26224184	A new era in the treatment of multiple sclerosis.	Med J Aust	2015
24986155	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.	J Clin Neurosci	2014
23886832	Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.	Multiple Sclerosis Journal	2014
24993136	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.	J Clin Neurosci	2014
24993135	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.	J Clin Neurosci	2014
23325588	A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).	Multiple Sclerosis Journal	2013
23726763	The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort.	Journal of Neuroimmunology	2013
22786591	Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk.	Neurology	2012
21833088	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.	Nature	2011
21177322	HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: a meta-analysis.	Multiple Sclerosis Journal	2011
20884011	Spinal cord involvement in multiple sclerosis: a correlative MRI and high-resolution HLA-DRB1 genotyping study.	Journal of the Neurological Sciences	2011